Recent phase 3 clinical trials reveal positive results for tazarotene lotion 0.045% in patients with moderate-to-severe acne.
Sol-Gel’s new investigational microencapsulated benzoyl peroxide and tretinoin combination cream, Twyneo, for the treatment of acne vulgaris shows promising results from recently released phase 3 data with both clinical trials meeting all primary endpoints.
Trifarotene may become the European Union’s first new retinoid molecule acne treatment for the face and trunk in 25 years following upcoming individual member state marketing approvals in 2020.
Results from an EU phase 3 clinical trial of a combination of betamethasone dipropionate and calcipotriene cream showed improved patient convenience, quality of life and efficacy compared to a betamethasone dipropionate and calcipotriene gel for patients with plaque psoriasis.
LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.
The U.S. FDA has granted Dermira with a Fast Track designation for its atopic dermatitis drug lebrikizumab following the start of phase 3 clinical trials to examine the efficacy, tolerability and safety of the drug.
Newly published results from a phase 3 study demonstrate the superiority of bimekizumab over adalimumab for plaque psoriasis.
A recent study examines the safety and efficacy of picosecond laser as a melasma treatment during a time when lasers are increasingly being used to treat the condition.
The United States Food and Drug Administration has granted Galderma’s nemolizumab a Breakthrough Therapy Designation following phase 2 results which suggests the drug is a considerable alleviant for pruritus associated with prurigo nodularis.
Collaboration between Leo Pharma and Portal Instruments brings needleless drug delivery device to forefront of dermatology industry
Leo Pharma A/S and Portal Instruments are now collaborating on a new needle-free handheld jet injector for patients that self-administer medicines for cutaneous diseases and ailments.